AKUMS Akums Drugs Q1 FY26 results (Apr–Jun 2025) and concall
Akums Drugs reported a resilient Q1 FY26 with a 2.4% YoY increase in total income to ₹1,051 crores and a 4% YoY growth in adjusted EBITDA to ₹129 crores, despite a challenging market with tepid volume growth and declining API prices. The company made significant strides in R&D with 27 DCGI approvals and expanded its global footprint with its first European Dossier approval for Rivaroxaban, backed by a strong cash surplus of ₹1,518 crores. Management guided for mid-single-digit growth in CDMO and aims for an 18% EBITDA margin for domestic branded formulations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 328 | 337 | 329 | 332 |
| EBITDA | 43 | 34 | 18 | 44 |
| Net profit | 50 | 41 | 28 | 45 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
